Peptide-YY3-36/glucagon-like peptide-1 combination treatment of obese diabetic mice improves insulin sensitivity associated with recovered pancreatic β-cell function and synergistic activation of discrete hypothalamic and brainstem neuronal circuitries

• Egile Nagusiak: Brandon B. Boland (Egilea), Rhianna C. Laker (Egilea), Siobhan O'Brien (Egilea), Sadichha Sitaula (Egilea), Isabelle Sermadiras (Egilea), Jens Christian Nielsen (Egilea), Pernille Barkholt (Egilea), Urmas Roostalu (Egilea), Jacob Hecksher-Sørensen (Egilea), Sara Rubek Sejthen (Egilea), Ditte Dencker Thorbek (Egilea), Arthur Suckow (Egilea), Nicole Burmeister (Egilea), Stephanie Oldham (Egilea), Sarah Will (Egilea), Victor G. Howard (Egilea), Benji M. Gill (Egilea), Philip Newton (Egilea), Jacqueline Naylor (Egilea), David C. Hornigold (Egilea), Jotham Austin (Egilea), Louise Lantier (Egilea), Owen P. McGuinness (Egilea), James L. Trevaskis (Egilea), Joseph S. Grimsby (Egilea), Christopher J. Rhodes (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2022-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Objective: Obesity-linked type 2 diabetes (T2D) is a worldwide health concern and many novel approaches are being considered for its treatment and subsequent prevention of serious comorbidities. Co-administration of glucagon like peptide 1 (GLP-1) and peptide YY3-36 (PYY3-36) renders a synergistic d...